Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...
pharmaphorum3d
Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T therapies
Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...
FiercePharma13h
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Novartis CEO on the impact of the U.S. election for pharma
Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on ...
pharmaphorum20d
Novartis spent $15bn on M&A last year, with more to come
The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...
Swissinfo11d
Novartis CEO: ‘Our strategy is bearing fruit’
Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.
Novartis Posts Results Above Estimates, Raises Outlook
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...